UY25702A1 - Desnaturalizantes para las sales aminas simpaticomiméticas - Google Patents

Desnaturalizantes para las sales aminas simpaticomiméticas

Info

Publication number
UY25702A1
UY25702A1 UY25702A UY25702A UY25702A1 UY 25702 A1 UY25702 A1 UY 25702A1 UY 25702 A UY25702 A UY 25702A UY 25702 A UY25702 A UY 25702A UY 25702 A1 UY25702 A1 UY 25702A1
Authority
UY
Uruguay
Prior art keywords
hydrochloride
inhibitor
water
sympathomimetic amine
compounds
Prior art date
Application number
UY25702A
Other languages
English (en)
Inventor
William S Bess
William Michael Nichols
Original Assignee
Warnert Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warnert Lambert Company filed Critical Warnert Lambert Company
Publication of UY25702A1 publication Critical patent/UY25702A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Composiciones farmacéuticas que comprenden una sal amina simpaticomimética (particularmente seleccionada del grupo compuesto por clorhidrato de pseudoefedrina, sulfato de pseudoefedrina, clorhidrato de efedrina, y clorhidrato de fenilpropanilamina) y al menos un inhibidor de combinación (particularmente seleccionado de sales de metal de transición y polímeros amino), donde dicho inhibidor de combinación en cantidades suficientes actúa tanto para interferir con el aislamiento de la amina simpaticomimética de la composición en otros compuestos farmacológicamente activos (especialmente seleccionados del grupo que consta de matanfetamina, anfetamina, metcatinona, y catinona) sin alterar significativamente la liberación de dicha composición farmacéutica en comparación con la composición no desnaturalizada; que además puede comprender un inhibidor de reacción (como por ejemplo compuestos polihidroxi insolubles en agua, compuestos polihidroxino no poliméricos solubles en agua y compuestos de éster solubles en éster) y/o un inhibidor de separación (seleccionado de celulosa soluble en agua, gomas polisacáridas, polímeros de óxido de polietileno, pólimeros de ácido acrílico, almidones, silicatos de aluminio y magnesio, polivinilpirrolidonas y arcillas). Por ejemplo las sales ácidas de las aminas simpatiocoiméticas, como el clorhidrato de la pseudoefedrina, actúan causando que las terminaciones nerviosas adrenérgicas liberan norepinefrina, estimulando los receptores alfa y beta de la norepinefrina, especialmente del tracto respiratorio superior.
UY25702A 1998-09-10 1999-09-09 Desnaturalizantes para las sales aminas simpaticomiméticas UY25702A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9971298P 1998-09-10 1998-09-10

Publications (1)

Publication Number Publication Date
UY25702A1 true UY25702A1 (es) 1999-11-17

Family

ID=22276270

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25702A UY25702A1 (es) 1998-09-10 1999-09-09 Desnaturalizantes para las sales aminas simpaticomiméticas

Country Status (22)

Country Link
US (4) US6359011B1 (es)
EP (1) EP1112089A1 (es)
JP (1) JP2002524534A (es)
KR (1) KR20010075021A (es)
CN (1) CN1201822C (es)
AR (1) AR032730A1 (es)
AU (2) AU771194B2 (es)
BR (1) BR9913575A (es)
CA (1) CA2339354A1 (es)
CO (1) CO5280050A1 (es)
CR (1) CR6106A (es)
GT (1) GT199900148A (es)
HK (1) HK1039898A1 (es)
HN (1) HN1999000156A (es)
MY (1) MY117971A (es)
NZ (1) NZ510012A (es)
PA (1) PA8481601A1 (es)
PE (1) PE20001034A1 (es)
SV (1) SV1999000148A (es)
TW (1) TW550071B (es)
UY (1) UY25702A1 (es)
WO (1) WO2000015261A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT199900148A (es) * 1998-09-10 2001-02-28 Desnaturalizantes para las sales aminas simpaticomimeticas.
AU7105501A (en) * 2000-07-17 2002-01-30 Yamanouchi Pharma Co Ltd Pharmaceutical composition improved in peroral absorbability
US7736670B2 (en) * 2000-11-30 2010-06-15 Vectura Limited Method of making particles for use in a pharmaceutical composition
ITMI20021074A1 (it) * 2002-05-20 2003-11-20 Actimex S R L Composizione ternaria comprendente una sostanza attiva e processo di comacinazione per la sua preparazione
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US20050220877A1 (en) * 2004-03-31 2005-10-06 Patel Ashish A Bilayer tablet comprising an antihistamine and a decongestant
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102004045037A1 (de) * 2004-09-15 2006-03-16 Basf Ag Pharmazeutische Darreichungsformen mit erschwerter Extrahierbarkeit eines Sympathomimetikums aus der Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
ATE493118T1 (de) * 2006-01-19 2011-01-15 Dow Global Technologies Inc Biologisch wirksame zusammensetzung mit ethylcellulose
US9238073B2 (en) 2006-04-12 2016-01-19 Wyeth Llc Pharmaceutical composition containing sympathomimetic amine salt and co-distillable additive
US8273798B2 (en) * 2007-06-04 2012-09-25 Shear Kershman Laboratories Tamper resistant lipid-based oral dosage form for opioid agonists
AU2008280801B2 (en) * 2007-07-23 2014-03-06 Kingsway Pharmaceuticals Inc. Therapeutic formulations for the treatment of cold and flu-like symptoms
MX2010004178A (es) 2007-10-19 2010-05-03 Otsuka Pharma Co Ltd Preparacion farmaceutica solida de tipo matriz.
BR112012001466A2 (pt) 2009-07-22 2020-08-11 Grünenthal GmbH forma de dosagem resistente à falsificação para opioides sensíveis à oxidação, seu processo de fabricação, e embalagem
US8901113B2 (en) * 2009-09-30 2014-12-02 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
CA2839123A1 (en) 2011-07-29 2013-02-07 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
MX348054B (es) 2011-07-29 2017-05-25 Gruenenthal Gmbh Tableta a prueba de alteracion que proporciona liberacion inmediata del farmaco.
WO2013036567A2 (en) * 2011-09-07 2013-03-14 Johnson Brent A Methods, compositions, and compounds for the reduction of illegal methamphetamine production
WO2013089986A1 (en) * 2011-12-12 2013-06-20 Product And Technology Partners Llc Improved denaturants for sympathomimetic amines
CA2880163A1 (en) * 2012-08-01 2014-02-06 Acura Pharmaceuticals, Inc. Stabilization of one-pot methamphetamine synthesis systems
AU2013352162B2 (en) 2012-11-30 2018-08-16 Acura Pharmaceuticals, Inc. Self-regulated release of active pharmaceutical ingredient
AU2014284333B2 (en) * 2013-07-03 2017-03-16 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
KR20160031526A (ko) 2013-07-12 2016-03-22 그뤼넨탈 게엠베하 에틸렌-비닐 아세테이트 중합체를 함유하는 템퍼 내성 투여형
BR112016010482B1 (pt) 2013-11-26 2022-11-16 Grünenthal GmbH Preparação de uma composição farmacêutica em pó por meio de criomoagem
AU2015237721B2 (en) 2014-03-26 2018-04-26 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release coated reservoir solid dosage form
WO2017040607A1 (en) 2015-08-31 2017-03-09 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
US10842750B2 (en) * 2015-09-10 2020-11-24 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
TW202002957A (zh) 2018-02-09 2020-01-16 德商歌林達有限公司 包含轉化抑制劑之麻黃素及其衍生物之抗損壞調配物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3169092A (en) 1963-09-26 1965-02-09 Richardson Merrell Inc Stabilization of amines by tartrazine and bisulfite
US3546142A (en) * 1967-01-19 1970-12-08 Amicon Corp Polyelectrolyte structures
US3773920A (en) * 1971-07-14 1973-11-20 Nikken Chemicals Co Ltd Sustained release medicinal composition
GB1593261A (en) 1976-07-23 1981-07-15 Inveresk Res Int Controlled release suppository
RO68771A2 (ro) * 1976-08-25 1980-08-15 Intreprinderea De Medicamente,Ro Unguent antipruriginos si sicativ
SU1146046A1 (ru) 1983-11-11 1985-03-23 Центральный Ордена Ленина Институт Усовершенствования Врачей Состав дл ретракции десны
US4493827A (en) 1983-11-14 1985-01-15 Ronald Valle Method of inducing sleep
US4601894A (en) * 1985-03-29 1986-07-22 Schering Corporation Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate
US4657757A (en) 1985-03-29 1987-04-14 Schering Corporation Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate
US4800087A (en) * 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
US4894239A (en) 1987-06-02 1990-01-16 Takeda Chemical Industries, Ltd. Sustained-release preparation and production thereof
ZA904021B (en) 1989-11-24 1991-02-27 Van Der Linde Leon Slimming preparations
CA2068402C (en) 1991-06-14 1998-09-22 Michael R. Hoy Taste mask coatings for preparation of chewable pharmaceutical tablets
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
EP1166801A1 (en) 1993-06-04 2002-01-02 Warner-Lambert Company Preparations containing silicon dioxide to improve the taste thereof
US5543405A (en) * 1993-10-22 1996-08-06 Keown; Wendy J. Composition and method for weight reduction and long term management of obesity
AUPM814994A0 (en) 1994-09-14 1994-10-06 Sterling Winthrop Inc. Codeine-containing formulations
US5529783A (en) 1994-12-19 1996-06-25 Mcneil-Ppc, Inc. Rotor granulation and coating of acetaminophen, pseudoephedrine, chlorpheniramine, and, optionally dextromethorphan
US5626878A (en) 1995-01-10 1997-05-06 Warner Lambert Company Reduction of electrostatic forces between magnesium trisilicate adsorbates
CA2250010C (en) 1996-04-10 2008-06-10 Warner-Lambert Company Denaturants for sympathomimetic amine salts
GT199900148A (es) * 1998-09-10 2001-02-28 Desnaturalizantes para las sales aminas simpaticomimeticas.

Also Published As

Publication number Publication date
NZ510012A (en) 2002-11-26
US20020082304A1 (en) 2002-06-27
WO2000015261A1 (en) 2000-03-23
HN1999000156A (es) 2003-08-01
CA2339354A1 (en) 2000-03-23
PE20001034A1 (es) 2000-10-18
KR20010075021A (ko) 2001-08-09
HK1039898A1 (zh) 2002-05-17
US20050256194A1 (en) 2005-11-17
JP2002524534A (ja) 2002-08-06
TW550071B (en) 2003-09-01
US6359011B1 (en) 2002-03-19
AU5915799A (en) 2000-04-03
CO5280050A1 (es) 2003-05-30
CN1316911A (zh) 2001-10-10
AR032730A1 (es) 2003-11-26
PA8481601A1 (es) 2001-04-30
US20060216268A1 (en) 2006-09-28
MY117971A (en) 2004-08-30
CR6106A (es) 2003-12-05
CN1201822C (zh) 2005-05-18
BR9913575A (pt) 2001-05-22
GT199900148A (es) 2001-02-28
SV1999000148A (es) 2000-09-11
AU2004202702B2 (en) 2007-11-22
EP1112089A1 (en) 2001-07-04
AU2004202702A1 (en) 2004-07-15
AU771194B2 (en) 2004-03-18

Similar Documents

Publication Publication Date Title
UY25702A1 (es) Desnaturalizantes para las sales aminas simpaticomiméticas
PE20070521A1 (es) 7-[2-[4-(6-FLUORO-3-METIL-1,2-BENCISOXAZOL-5-IL)-1-PIPERAZINIL]ETIL]-2-(1-PROPINIL)-7H-PIRAZOL-[4,3-E]-[1,2,4]-TRIAZOL-[1,5-C]-PIRIMIDIN-5-AMINA COMO ANTAGONISTA DEL RECEPTOR DE ADENOSINA A2a
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
PE20001415A1 (es) Composiciones que tienen suministro mejorado de activos
CO5200844A1 (es) Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes
BR0313160A (pt) Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto
ECSP077999A (es) Formulaciones de una sal de bupropion de liberación modificada
CL2011000314A1 (es) Composición farmacéutica estable que comprende linaclotida; método de preparación; y uso para preparar un medicamento útil para tratar un desorden gastrointestinal.
BR0214199A (pt) Composições de fenóxi amina para liberar agentes ativos, forma de unidade de dosagem e método de administração
BR0314379A (pt) Quinazolinonas espirocondensadas e a sua utilização como inibidores de fosfodiesterase
CO2023002852A2 (es) Péptidos funcionalizados como agentes antivirales
WO2006042324A3 (en) Antifungal composition applicable to body tissue, preferably nails
AR025307A1 (es) Compuesto de liberacion sostenida de un peptido, microparticulas, composicion farmaceutica y el uso de dicho compuesto para la fabricacion de un medicamento
BRPI0419213A (pt) formas secas de formulação de dosagem de ácido biliar solubilizada aquosa: preparação e usos destas
CO2022002731A2 (es) Formas en estado sólido de (s)-2-(((s)-6,8-diflúor-1,2,3,4-tetrahidronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2-il)-1h-imidazol-4-il)pentanamida y usos de la misma
BR0308786A (pt) Derivados de ftalimido como inibidores da monoamina oxidase b
BRPI0513549A (pt) composições farmacêuticas para o tratamento de leishmaniose
DE69933388D1 (de) Pharmazeutische Lösungen VON TRIPHENYLETHYLEN-ANTIÖSTROGENEN
CO5150213A1 (es) Concentrado oral de sertralina
UY27920A1 (es) Combinaciones de epinastina, pseudoefedrina y metilefedrina como nuevas formulaciones farmaceuticas
RU2003126176A (ru) Кислотно-аддитивные соли тербинафина и яблочной кислоты
UY28111A1 (es) Nueva forma de dosificación oral de liberación inmediata
BRPI0409441A (pt) sal de amÈnio, composição farmacêutica, e, método para tratamento de um mamìfero sofrendo ou susceptìvel a cáncer
EP3612188B1 (en) Heterobivalent ligands suitable for use in the treatment of parkinson's disease
ECSP993128A (es) Desnaturalizantes para las sales aminas simpaticomimeticas

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20100519